Skip to main content
Signal8

Syra Health Corp (SYRA) Form 8-K — Nov 3, 2026

$SYRAForm 8-KItems 2.02, 9.01Filed Nov 3, 2026, 9:29 AM ET0001493152-26-049729Original filing

Syra Health reported its third consecutive profitable quarter with record revenue of $2.6 million in Q3 2026, up 52% year-over-year from $1.7 million. Net income swung to $344,610 from a $(225,902) loss a year ago, with EPS of $0.02 versus $(0.02), and gross margin hit a company-record 46.3%, up 1,340 basis points. Nine-month net income reached $835,831 versus a $(761,763) loss last year, operating cash flow was $975,023, and the company ended the quarter with $2.4 million in cash and no long-term debt.

Key figures

Eps
0.02
Revenue
2557295
Guidance
Company remains on track for full-year profitability in 2026; expects quarter-to-quarter variability from RFP- and contract-driven timing.
Net Income
344610
Revenue Yoy
52%
Total Assets
4225390
Cash Position
2383413
Gross margin
46.3%
Ebitda q3 2026
301725
Long term debt
none
Net income 9m 2026
835831
Operating cash flow 9m
975023
Gross margin prior year
32.9%
Total debt notes payable
179272

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Syra Health Corp (SYRA) Form 8-K — Nov 3, 2026: AI Analysis | Signal8